Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has a primary diagnosis of major depressive episode according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.~* The reported duration of the current major depressive episode is at least 3 months.~* Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥26.~* A male or a female of childbearing potential who is sexually active agrees to use adequate contraception from Screening throughout the duration of the study and for 1 month after the last dose of study medication.~Exclusion Criteria:~* Has 1 or more the following:~  * Any current psychiatric disorder other than major depressive disorder as defined in the DSM-IV-TR.~ * Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.~ * Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR. (must have negative urine drug screen prior to Baseline).~ * Presence or history of a clinically significant neurological disorder (including epilepsy).~ * Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).~* Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression Rating Scale, or has made a suicide attempt in the previous 6 months.~* Currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.~* Has a clinically significant unstable illness.~* Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.~* Has received electroconvulsive therapy within 6 months prior to Screening.~* Has an alanine aminotransferase, aspartate aminotransferase, or total bilirubin level \> 1.5 times the upper limit of normal.~* Has a serum creatinine of \> 1.5 × upper limit of normal.~* Has a previous history of cancer that had been in remission for less than 5 years.~* Has thyroid stimulating hormone value outside the normal range.~* Has an abnormal electrocardiogram.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine 1 mg (Type: EXPERIMENTAL): Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks.
- Vortioxetine 5 mg (Type: EXPERIMENTAL): Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks.
- Vortioxetine 10 mg (Type: EXPERIMENTAL): Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).